Table 1.

Characteristics of studies included in the systematic review.

References	Country	Specimen	Case (n) / Control (n)	Age (Case)	Methods	miRNAs	Patient characteristics (Control)	Max time from onset until sample acquisition	AUC	Sensitivity	Specificity
Li et al, 2019[23]	China	Serum	41/32	62.95 ± 11.04	SYBR	miRNA-208	AMI/Non-AMI ACS	Within 3 h	0.868	70%	97.5%
Agiannitopoulos et al, 2018[22]	Greece	Plasma	50/50	62.12 ± 10.99	TaqMan	miRNA-208a	AMI/Healthy	Within 24 h	0.999	98%	100%
Liu et al, 2018[24]	China	Plasma	145/30	67	SYBR	miRNA-208	STEMI/Healthy	Within 2–4 h	0.994	90%	100%
Li et al, 2015[13]	China	Plasma	87/87	56.93 ± 9.17	SYBR	miRNA-208b	AMI/Healthy	Within 4 h	0.674	59.8%	73.6%
Liu et al, 2015[26]	China	Plasma	70/72	64.2 ± 11.2	TaqMan	miRNA-208b	AMI/Healthy	Within 2 h	0.72	65%	90%
Devaux et al, 2015[21]	Luxembourg	Plasma	224/931	72 (61 ± 80)	TaqMan	miRNA-208b	AMI/Non-AMI ACS	Within 12 h	0.76	64.7%	80.2%
Gidlof et al, 2013[20]	Sweden	Plasma	318/88	64.56 ± 2.7	SYBR	miRNA-208b	AMI/Non-AMI ACS	Within 72 h	0.82	79%	70%
Li et al, 2013[25]	China	Plasma	117/100	62.7 ± 11.4	TaqMan	miRNA-208	AMI/Healthy	Within 2 h	0.778	75.8%	73.1%
Li et al, 2013[19]	China	Plasma	67/32	63.84 ± 11.17	SYBR	miRNA-208b	AMI/Healthy	Within 12 h	0.89	82.4	99.8%
Devaux et al, 2012[18]	Netherlands	Plasma	510/87	62 (0.32–91)	TaqMan	miRNA-208b	AMI/Healthy	Within 12 h	0.9	79.5%	99.8%
Gidlof et al, 2011[17]	Sweden	Plasma	9/11	64.56 ± 2.7	SYBR	miRNA-208b	STEMI/Healthy	Within 12 h	1	1	1
Corsten et al, 2010[16]	Netherlands	Plasma	32/36	62 ± 13	SYBR	miRNA-208b	AMI/Non-AMI ACS	Within 12 h	0.965	90.6%	94.1%
Wang et al, 2010[12]	China	Plasma	33/33	63.5 ± 10.1	TaqMan	miRNA-208	AMI/Non-AMI ACS	Within 12 h	0.999	98%	100%